Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
View Patent ↗This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the lumenal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.
1. A composition comprising a purified protein which specifically binds to the gastro-intestinal tract receptor HPT1 (SEQ ID NO:178), wherein the purified protein is bound to a material comprising an active agent selected from the group consisting of an imaging agent, a drug, and an antigen, and wherein the protein comprises the amino acid sequence of SEQ ID NO:50 or a portion thereof of at least 6 contiguous amino acids that mediates binding to HPT1.
2. The composition of claim 1 wherein the protein comprises the amino acid sequence of SEQ ID NO:50.
3. The composition of claim 1 wherein the material is a particle containing the active agent.
4. The composition of claim 1 wherein the material is a slow-release device containing the active agent.
5. The composition of claim 1 wherein the active agent is a drug.
6. The composition of any one of claims 1 and 3 - 5 wherein the purified protein is not more than 40 amino acids in length.
7. The composition of any one of claims 1 and 3 - 5 wherein the purified protein is not more than 30 amino acids in length.
8. The composition of any one of claims 1 and 3 - 5 wherein the purified protein is not more than 20 amino acids in length.
9. The composition of any one of claims 1 , 2 and 3 - 5 wherein said protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.
10. A pharmaceutical composition comprising a therapeutically effective amount of the composition of any one of claims 1 , 2 and 3 - 5 , and a pharmaceutically acceptable carrier.
11. A composition comprising a chimeric protein wherein the chimeric protein is bound to a material comprising an active agent selected from the group consisting of an imaging agent, a drug, and an antigen, and wherein the chimeric protein comprises (i) an amino acid sequence fused via a covalent bond to (ii) a second amino acid sequence which specifically binds to the gastro-intestinal tract receptor, HPT1 (SEQ ID NO:178), and wherein the second amino acid sequence comprises SEQ ID NO:50 or a portion thereof at least 6 contiguous amino acids that mediates binding to HPT1.
12. The composition of claim 11 wherein the protein comprises the amino acid sequence of SEQ ID NO:50.
13. The composition of claim 11 wherein the material is a particle containing the active agent.
14. The composition of claim 11 wherein the material is a slow-release device containing the active agent.
15. The composition of claim 11 wherein the active agent is a drug.
16. The composition of any one of claims 11 and 13 - 15 wherein the purified protein is not more than 40 amino acids in length.
17. The composition of any one of claims 11 and 13 - 15 wherein the purified protein is not more than 30 amino acids in length.
18. The composition of any one of claims 11 and 13 - 15 wherein the purified protein is not more than 20 amino acids in length.
19. The composition of any one of claims 11 , 12 and 13 - 15 wherein said chimeric protein facilitates the transport of the active agent through human or animal gastrointestinal tissue.
20. A pharmaceutical composition comprising a therapeutically effective amount of the composition of any one of claims 11 , 12 and 13 - 15 , and a pharmaceutically acceptable carrier.
21. A composition comprising a purified protein which specifically binds to the gastro-intestinal tract receptor HPT1 (SEQ ID NO:178), wherein the purified protein is bound to a drug, said drug being of value in the treatment of a mammalian disease or disorder, and wherein the protein comprises the amino acid sequence of SEQ ID NO:50 or portion thereof of at least 6 contiguous amino acids that mediates binding to HPT1.
22. The composition of claim 21 wherein the protein comprises the amino acid sequence of SEQ ID NO:50.
23. The composition of claim 21 wherein the purified protein is not more than 40 amino acids in length.
24. The composition of claim 21 wherein the purified protein is not more than 30 amino acids in length.
25. The composition of claim 21 wherein the purified protein is not more than 20 amino acids in length.
26. The composition of claim 21 or 22 wherein said protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.
27. A pharmaceutical composition comprising a therapeutically effective amount of the composition of claims 21 or 22 and a pharmaceutically acceptable carrier.
28. A composition comprising a purified protein which specifically binds to the gastro-intestinal tract receptor HPT1 (SEQ ID NO:178), wherein the purified protein is coated onto or absorbed onto or covalently bonded to the surface of a nanoparticle or microparticle, and wherein the protein comprises the amino acid sequence of SEQ ID NO:50 or a portion thereof of at least 6 contiguous amino acids that mediates binding to HPT1.
29. The composition of claim 28 wherein the protein comprises the amino acid sequence of SEQ ID NO:50.
30. The composition of claim 28 wherein the nanoparticle or microparticle contains a drug.
31. The composition of claim 28 wherein the nanoparticle or microparticle is a slow-release device.
32. The composition of any one of claims 28 , 30 , and 31 wherein the purified protein is not more than 40 amino acids in length.
33. The composition of any one of claims 28 , 30 , and 31 wherein the purified protein is not more than 30 amino acids in length.
34. The composition of any one of claims 28 , 30 , and 31 wherein the purified protein is not more than 20 amino acids in length.
35. The composition of any one of claims 28 , 30 , and 31 wherein said protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.
36. A pharmaceutical composition comprising a therapeutically effective amount of the composition of any one of claims 28 , 29 , 30 and 31 , and a pharmaceutically acceptable carrier.
37. A nanoparticle or a microparticle comprising a purified protein which specifically binds to the gastro-intestinal tract receptor, HPT1 (SEQ ID NO:178), wherein the purified protein comprises the amino acid sequence of SEQ ID NO:50 or a portion thereof of at least 6 contiguous amino acids that mediates binding to HPT1.
38. The composition of claim 37 wherein the protein comprises the amino acid sequence of SEQ ID NO:50.
39. The composition of claim 37 wherein the purified protein is not more than 40 amino acids in length.
40. The composition of claim 37 wherein the purified protein is not more than 30 amino acids in length.
41. The composition of claim 37 wherein the purified protein is not more than 20 amino acids in length.
42. The composition of claim 37 or 38 wherein said protein facilitates the transport of the active agent through human or animal gastro-intestinal tissue.
43. A pharmaceutical composition comprising a therapeutically effective amount of the composition of claim 37 or 38 , and a pharmaceutically acceptable carrier.
44. A pharmaceutical composition comprising a therapeutically effective amount of a chimeric protein comprising (i) a first protein comprising at least 6 contiguous amino acids of an amino acid sequence comprising SEQ ID NO:50, said contiguous amino acids being capable of specifically binding to the gastro-intestinal tract receptor HPT1 (SEQ ID NO:178), said first protein being fused via a covalent bond to (ii) a second protein, said second protein being a drug; and a pharmaceutically acceptable carrier.
45. A pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a chimeric protein comprising (i) a first protein comprising at least 6 contiguous amino acids of an amino acid sequence comprising SEQ ID NO:50, said contiguous amino acids capable of specifically binding to the gastrointestinal tract receptor HPT1 (SEQ ID NO:178), said first protein being fused via a covalent bond to (ii) a second protein, said second protein being a drug; and a pharmaceutically acceptable carrier.